For twenty years, American healthcare consolidation ran on debt. Private equity bought practices using leveraged buyout financing, platform expansions used senior debt to fund add-on acquisitions, and community banks and SBA lenders wrote practice-acquisition loans at 10-year amortization schedules. Private credit funds stepped in where banks wouldn't, layering unitranche facilities onto mid-market platforms. The entire specialty-consolidation thesis assumed that debt would do the heavy lifting on every new platform build, and that era is now ending. The question for anyone thinking about capital deployment into physician-led healthcare isn't whether debt markets will recover, but what happens to ophthalmology consolidation in a world where the debt machinery that built the category doesn't work anymore.

The Debt Market That Disappeared

Healthcare bankruptcy filings reached a six-year high in 2024, per Gibbins Advisors, and ten physician practice Chapter 11 filings hit the record that year, up 60% year-over-year, driven largely by PE-backed practice platforms unable to service debt against declining Medicare reimbursement. The 2.83% Medicare Physician Fee Schedule cut in FY25 was explicitly flagged as a primary driver. Healthcare PE defaults in Q2 2025 hit 21 companies representing more than $27 billion of debt, up from 15 companies and $15 billion in Q1. PE-backed firms now default at roughly twice the rate of non-PE-backed firms per Moody's, and approximately 80% of rated North American healthcare companies now hold speculative-grade ratings, compared to 71% in 2010.

The Federal Reserve's October 2025 Senior Loan Officer Opinion Survey reported modest net shares of banks tightening standards on commercial and industrial loans to firms of all sizes, with major net shares of lenders citing "worsening of industry-specific problems" and "reduced tolerance for risk" as reasons for tightening. The survey confirmed what practice brokers have been saying for over a year: the commercial lending environment for new healthcare platforms has structurally shifted. On the SBA side, Standard Operating Procedure 50 10 8, effective June 1, 2025, reinstated IRS 4506-C verification requirements, required historical-cash-flow debt service coverage ratios of at least 1.15x (with lenders routinely applying 1.25-1.50x in practice), and reversed the Biden-era "Do What You Do" framework that had permitted projections-based underwriting. The practical effect is that SBA underwriting can no longer finance practice acquisitions where the practice is in a turnaround situation or where the new owner's entity has no trailing financial history. The SBA 7(a) program also carries a hard $5 million cap per borrower per three-digit NAICS code, which means any ophthalmology platform acquirer hits that ceiling with a single mid-size transaction and a platform intending to execute multiple acquisitions over time runs out of SBA capacity after its first or second deal.

Why the Model Can't Adapt

The standard healthcare cash-flow loan structure requires maximum leverage of 3.0-4.5x EBITDA, minimum fixed charge coverage ratios of 1.1-1.75x, and a borrower entity with trailing EBITDA that supports the debt service. Middle-market senior debt averaged 4.5x leverage across healthcare deals in 2024 per PGIM Fixed Income data, and three structural problems break that model for new physician-led platforms. First-time MSO entities have zero trailing EBITDA because the entity was formed to execute its first acquisition, which means there's no financial history to underwrite, and no matter how strong the underlying practice is or how experienced the operators are individually, the MSO itself is a blank-slate borrower that banks route automatically to rejection.

Turnaround practices, which are often the practices that need new ownership most, frequently show declining trailing-twelve-month EBITDA in the year before acquisition, and that's exactly what makes them attractive. A practice with a 75-year-old owner who's reduced hours and hasn't reinvested in equipment can be restored to prior performance by a successor physician and operational team, but commercial lenders underwrite trailing cash flow rather than prospective cash flow, so a practice showing declining EBITDA in the twelve months before acquisition gets rejected on underwriting grounds even when the turnaround thesis is sound. Compounding both issues, Medicare and Medicaid recoupment risk extends up to six years retroactively per ABA Banking Journal analysis (Lodoen, Herring, Martel, 2021), and that retroactive exposure makes federal-payor accounts receivable effectively "phantom collateral" from a lender's perspective. Generalist banks have historically avoided physician practice acquisition lending, and the specialized healthcare lenders who do operate in the space apply far more conservative terms than equivalent non-healthcare operators would face. None of these structural constraints loosen when the Fed cuts rates because they're baked into how commercial healthcare lending underwrites risk.

What Private Credit Did, and Why It's Not the Answer Either

Private credit stepped into much of the territory commercial banks vacated after 2008. Direct lenders, specialty healthcare credit funds, and unitranche shops built massive books of business funding PE-backed healthcare platforms over the last decade, and that market broke too. TCW's August 2025 analysis of private credit reported that 11% of Lincoln International-valued loans in Q1 2025 carried payment-in-kind (PIK) interest components, compared to effectively 0% at origination for 56% of those loans. Moody's shadow default rate on private credit portfolios sits near 6%, versus reported 2.1% per KBRA, and PIK conversion and shadow defaults are evidence of borrowers who can't service debt being papered over instead of restructured, which delays the reckoning but doesn't resolve it.

EyeCare Partners' April-May 2024 debt exchange is the visible case in ophthalmology. The platform's first-lien debt traded at roughly 54 cents on the dollar ahead of the restructuring per Bloomberg reporting, over 98% of first-lien holders and 91% of second-lien holders participated in the out-of-court liability management exercise, and Partners Group and existing lenders injected $275 million of new super-priority money with maturities extended to 2027. That restructuring didn't fix EyeCare Partners; it bought time, and the platform's credit trajectory continued to deteriorate through late 2025, with the maturity wall now closer than the restructuring was intended to push it. American Physician Partners filed Chapter 11 in September 2023 with $500 million to $1 billion in liabilities, a different specialty (emergency medicine) running the same structural pattern. Covenant Physician Partners avoided distressed exchange only when KKR paid lenders at par in Q1 2024 before quietly selling to USPI/Tenet. These aren't isolated cases but the pattern of what happens when leveraged healthcare platforms hit operational headwinds.

The Opportunity That the Debt Failure Creates

The end of the debt era doesn't mean ophthalmology consolidation stops. It means the consolidation that continues has to be financed differently. Strategic acquirers like pharma distributors Cencora and McKesson, payors like Humana, and specialty aggregators like Cardinal Health all have balance-sheet capacity to do large transactions without requiring external debt financing, which is what drove Cencora-RCA at $4.4 billion in January 2025, McKesson-PRISM at $850 million in April 2025, and Cardinal-Solaris at $1.9 billion in August 2025. Strategic corporate buyers are absorbing the trophy assets from PE exits because they can, but they have minimum deal thresholds. Cardinal's specialty platform serves 3,000+ providers across 32 states, McKesson and Cencora operate at similar scales, and these buyers don't transact on sub-$10 million ophthalmology practices because the transaction economics don't work for their infrastructure.

What remains is the long tail of independent ophthalmology practices. Roughly 4,300 solo ophthalmologists are expected to exit practice through retirement or transition by 2030, most of those practices are sub-$10 million in annual revenue, and none of them will be absorbed by Cencora, McKesson, or Cardinal. They won't be absorbed by PE platforms either, because PE can't finance new platform builds in the current debt environment and existing PE platforms are in forced-seller mode instead of acquisition mode. They won't be absorbed by hospitals, because hospital systems lost roughly $307K per employed physician on average in Q4 2024 and are divesting rather than expanding physician employment. That leaves patient capital: operator-investor structures that don't require traditional debt financing, don't require a 5-year PE exit cycle, and don't need to match the transaction size thresholds of strategic corporate buyers. Permanent-hold platforms built on operator capital deployed as direct investment rather than LBO leverage.

This isn't theoretical. The capital structures that built Berkshire Hathaway, Constellation Software, and multi-generational family office holding companies are the structures that fit American ophthalmology's remaining solo practice base. Patient capital acquiring practices at sub-$10 million transaction sizes, retaining them indefinitely, compounding cash flow over decades rather than exiting to the next fund. The end of leveraged ophthalmology isn't the end of ophthalmology consolidation; it's the transition from debt-financed LBO consolidation to operator-led patient-capital consolidation. Different capital, different structure, different time horizons. For capital that has been looking for a physician-led specialty where patient-capital structures actually fit the underlying asset, American ophthalmology in 2026 is one of the clearest opportunities available.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com